STOCK TITAN

Lexicon Pharmaceuticals, Inc. - LXRX STOCK NEWS

Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.

Lexicon Pharmaceuticals, Inc. (symbol: LXRX) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs to treat serious human diseases. Utilizing advanced genetics, Lexicon has developed a robust pipeline of novel drug candidates aimed at addressing a wide range of medical needs.

Research and Development: Lexicon's research team employs gene knockout technology to investigate thousands of potential drug targets in the human genome. This approach has enabled the company to gain a deep understanding of target biology, leading to the identification of new therapeutic interventions. Lexicon's systematic drug discovery process integrates recombinant DNA and chemistry technologies, allowing for the effective evaluation and advancement of promising drug candidates.

Key Products and Pipeline: Among Lexicon's notable drug candidates are LX9211, an orally delivered small molecule for neuropathic pain, and sotagliflozin (marketed as INPEFA®), another orally delivered small molecule for heart failure and type 1 diabetes. Sotagliflozin is a dual inhibitor of SGLT2 and SGLT1, proteins responsible for glucose regulation. The drug has demonstrated efficacy in clinical trials involving around 20,000 patients across multiple conditions, including diabetes and chronic kidney disease.

Recent Achievements: Lexicon has successfully launched INPEFA® in the United States, marking a significant milestone in its commercialization efforts. The company continues to advance its other drug candidates through clinical and preclinical development, with a focus on neuropathic pain, diabetes, metabolism, and other therapeutic areas.

Financial Condition: As of the latest reports, Lexicon's research and development expenses have increased, reflecting its commitment to advancing its pipeline. The company is actively engaged in investor and media relations, providing regular updates on its financial position, strategic alliances, and regulatory progress.

Partnerships and Strategic Alliances: Lexicon's unique expertise in genomics has attracted several strategic partnerships aimed at enhancing its drug discovery and development capabilities. These alliances support the company's mission to pioneer medicines that transform patients' lives.

For more detailed information about Lexicon Pharmaceuticals and its latest developments, visit their official website.

Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in the Jefferies London Global Healthcare Conference. CEO Mike Exton will join a moderated discussion on Wednesday, November 20, 2024, at 9:00 am GT. The event will be accessible via live webcast in the 'Events' section of Lexicon's website, with the recording remaining available for two weeks after the original broadcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
conferences
-
Rhea-AI Summary

Lexicon Pharmaceuticals (LXRX) announced the publication of research findings on sotagliflozin in the Journal of American Society of Nephrology. The study analyzed the drug's efficacy and safety when combined with insulin in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD). Key findings show that sotagliflozin achieved similar HbA1c reductions in both CKD and non-CKD patients, with significant placebo-adjusted reductions of -0.4% for 200mg and -0.3% to -0.4% for 400mg doses. The drug demonstrated a lower to neutral risk of severe hypoglycemia and did not significantly increase diabetic ketoacidosis risk. The FDA has set a PDUFA date of December 20, 2024, for Zynquista (sotagliflozin).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none
-
Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming third quarter 2024 financial results conference call and webcast, scheduled for November 12, 2024, after market close. The management will host a conference call and live webcast at 5:00 p.m. ET to discuss financial results and provide a business update. The event will be accessible via phone and webcast, with replay options available for 7 days via phone and 14 days via webcast on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
conferences earnings
Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) presents data on LX9851, a novel anti-obesity compound, at Obesity Week 2024. Two preclinical studies demonstrate significant findings: First, LX9851 showed substantial reductions in weight, food intake, and fat mass in diet-induced obese mice, particularly when combined with semaglutide. The combination therapy prevented weight regain after semaglutide discontinuation and improved liver-related endpoints.

Second study revealed LX9851's mechanism of action through ACSL5 inhibition, which activates the ileal brake - a natural satiety pathway. The company plans to file an Investigational New Drug (IND) application in 2025 for this first-in-class, orally bioavailable molecule.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
-
Rhea-AI Summary

Lexicon Pharmaceuticals (LXRX) received an unfavorable vote from the FDA Advisory Committee regarding Zynquista, its oral SGLT1/SGLT2 inhibitor for type 1 diabetes (T1D) and chronic kidney disease (CKD) patients. The committee voted 11-3 against the drug's benefits outweighing its risks. Despite the negative outcome, some committee members expressed support for the drug in certain T1D and CKD sub-populations. The FDA's final decision is expected by December 20, 2024. Currently, only 20% of T1D patients achieve adequate glycemic control with insulin alone, highlighting the potential market need for Zynquista as the first oral medication for T1D patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.69%
Tags
-
Rhea-AI Summary

Lexicon Pharmaceuticals announced a new analysis of its Phase 3 SCORED clinical trial demonstrating sotagliflozin's protective effects in patients with diabetic kidney disease (DKD). The post hoc analysis evaluated sotagliflozin's effect on Estimated Glomerular Filtration Rate (eGFR) slope versus placebo. Results showed a placebo-adjusted acute decline in eGFR of -2.59 ml/min/1.73m2/year across 10,574 participants. Notably, sotagliflozin demonstrated greater benefit on chronic slope with increasing baseline albuminuria. The findings will be presented at Kidney Week 2024 in San Diego.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced the completion of screening for its Phase 2B PROGRESS study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP). The company expects to complete enrollment ahead of schedule, with top-line data now anticipated in Q1 2025, earlier than the previously expected Q2 2025.

LX9211, an orally-delivered, potent, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1), has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP. The PROGRESS study, which began in December 2023, aims to enroll adult patients with moderate to severe DPNP, allowing them to continue their current pain therapy. The primary endpoint is a reduction of Average Daily Pain Score (ADPS) at 8 weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
-
Rhea-AI Summary

Viatris Inc. (Nasdaq: VTRS) has entered an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin in all markets outside the U.S. and Europe. Sotagliflozin, approved by the FDA in May 2023, reduces cardiovascular risks in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

This agreement leverages Viatris' expertise in cardiovascular diseases and its Global Healthcare Gateway®. Viatris will pay Lexicon an upfront payment of $25 million, with additional potential contingent payments including regulatory milestones, sales milestones, and tiered royalties ranging from low-double-digit to upper-teens on annual net sales. Viatris will handle regulatory and commercialization activities in licensed territories, while Lexicon will provide clinical and commercial supply of sotagliflozin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.24%
Tags
none
-
Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced the presentation of study design details for SONATA-HCM, a Phase 3 clinical trial evaluating sotagliflozin as a potential treatment for adults with hypertrophic cardiomyopathy (HCM). The presentation will take place at the virtual Hypertrophic Cardiomyopathy Medical Society (HCMS) 2024 Scientific Sessions.

The multinational study aims to enroll adults with symptomatic obstructive or non-obstructive HCM at 130 sites across 20 countries. Patient randomization has already begun. The trial design is intended to support a supplemental new drug application (sNDA) with a broad label for both HCM types. Experts highlight the significant unmet needs in HCM treatment and express optimism about sotagliflozin's potential efficacy in this patient population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
conferences clinical trial
Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that Jeff Wade, president and chief operating officer, will step down on September 30, 2024, to pursue new opportunities. Wade has served in various leadership roles at Lexicon for 25 years. The company is currently searching for a new chief financial officer. Lexicon's chairman and CEO expressed gratitude for Wade's contributions, highlighting his role in the potential approval of sotagliflozin for type 1 diabetes and CKD, and the development of LX9211 for diabetic peripheral neuropathic pain. The company remains confident in its current leadership team and future prospects, with several near-term and long-term catalysts expected to drive value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
none

FAQ

What is the current stock price of Lexicon Pharmaceuticals (LXRX)?

The current stock price of Lexicon Pharmaceuticals (LXRX) is $1.27 as of November 8, 2024.

What is the market cap of Lexicon Pharmaceuticals (LXRX)?

The market cap of Lexicon Pharmaceuticals (LXRX) is approximately 445.0M.

What does Lexicon Pharmaceuticals specialize in?

Lexicon Pharmaceuticals specializes in the discovery, development, and commercialization of innovative drugs to treat serious human diseases using advanced genetic research.

What are some key drug candidates developed by Lexicon?

Key drug candidates include LX9211 for neuropathic pain and sotagliflozin (INPEFA®) for heart failure and type 1 diabetes.

What technology does Lexicon use for drug discovery?

Lexicon employs gene knockout technology and integrates recombinant DNA and chemistry technologies in its drug discovery process.

What recent achievements has Lexicon Pharmaceuticals made?

Lexicon has successfully launched INPEFA® in the U.S. and continues to advance its other drug candidates through clinical and preclinical development.

What diseases do Lexicon’s drug candidates target?

Lexicon’s drug candidates target a range of conditions including neuropathic pain, heart failure, type 1 diabetes, and various metabolic disorders.

How does Lexicon's sotagliflozin work?

Sotagliflozin is a dual inhibitor of SGLT2 and SGLT1, which are proteins responsible for glucose regulation in the kidney and gastrointestinal tract.

What is the focus of Lexicon's research and development efforts?

Lexicon focuses on discovering and developing medicines that safely and effectively treat diseases by targeting specific proteins identified through genomics research.

How can I get more information about Lexicon Pharmaceuticals?

For more information, visit Lexicon Pharmaceuticals' official website at http://www.lexpharma.com.

What strategic partnerships has Lexicon formed?

Lexicon has formed various strategic alliances to enhance its drug discovery and development capabilities, leveraging its expertise in genomics.

Where can I find the latest financial updates on Lexicon?

Latest financial updates and investor information can be found on Lexicon’s official website under the investor relations section.

Lexicon Pharmaceuticals, Inc.

Nasdaq:LXRX

LXRX Rankings

LXRX Stock Data

445.03M
361.49M
1.15%
79.32%
7.65%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
THE WOODLANDS